Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives

Contraception

Volumn 77, Issue 6, 2008, Pages 415-419

  Hampton, R Moss ^a   Zhang, Huabin F ^b   Barnowski, Christopher ^c   Wan, George J ^d  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JOHNSON AND JOHNSON   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Age; Body weight; Cycle control; Oral contraceptive

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLEEDING; BODY MASS; BODY WEIGHT; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SECONDARY ANALYSIS; SPOTTING;

ADOLESCENT; ADULT; AGE FACTORS; BODY WEIGHT; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUATION; METRORRHAGIA; MIDDLE AGED; NORETHINDRONE; NORGESTREL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 43349097649     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.02.007     Document Type: Article

References (17)

1. Bensyl D.M., Iuliano D.A., Carter M., Santelli J., and Gilbert B.C. Contraceptive use - United States and territories, Behavioral Risk Factor Surveillance System, 2002. MMWR Surveill Summ 54 (2005) 1-72
2. Anonymous. Pill won't budge from no. 1 spot: half of women leave exams with OCs. Contracept Technol Update 21 (2000) 101-104
3. Petitti D.B. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 349 (2003) 1443-1450
4. Rosenberg M.J., Meyers A., and Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 60 (1999) 321-329
5. Bannemerschult R., Hanker J.P., Wunsch C., Fox P., Albring M., and Brill K. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles. Contraception 56 (1997) 285-290
6. Hampton R.M., Short M., Bieber E., et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 63 (2001) 289-295
7. Food and Drug Administration, Division of Reproductive and Urologic Products, Office of Drug Evaluation III. Advisory Committee for Reproductive Health Drugs General Meeting on Contraceptives, January 23 and 24, 2007. FDA Briefing Document. Available at (2007). http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4274b1-01-FDA.pdf Accessed on September 18
8. Seibert C., Barbouche E., Fagan J., Myint E., Wetterneck T., and Wittemyer M. Prescribing oral contraceptives for women older than 35 years of age. Ann Intern Med 138 (2003) 54-64
9. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
10. Rowland A.S., Baird D.D., Long S., et al. Influence of medical conditions and lifestyle factors on the menstrual cycle. Epidemiology 13 (2002) 668-674
11. Astrup K., Olivarius N.F., Moller S., Gottschau A., and Karlslund W. Menstrual bleeding patterns in pre- and perimenopausal women: a population-based prospective diary study. Acta Obstet Gynecol Scand 83 (2004) 197-202
12. Santoro N., Lasley B., McConnell D., et al. Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: The Study of Women's Health across the Nation (SWAN) Daily Hormone Study. J Clin Endocrinol Metab 89 (2004) 2622-2631
13. Gallicchio L., Visvanathan K., Miller S.R., et al. Body mass, estrogen levels, and hot flashes in midlife women. Am J Obstet Gynecol 193 (2005) 1353-1360
14. Thorneycroft I.H. Cycle control with oral contraceptives: a review of the literature. Am J Obstet Gynecol 180 (1999) 280-287
15. Carr B.R., and DelConte A. Using a low-dose contraceptive in women 35 years of age and over: 20 microg estradiol/100 microg levonorgestrel. Contraception 65 (2002) 397-402
16. Holt V.L., Scholes D., Wicklund K.G., Cushing-Haugen K.L., and Daling J.R. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 105 (2005) 46-52
17. Fogle R.H., Murphy P.A., Westhoff C.L., and Stanczyk F.Z. Does St. John's wort interfere with the antiandrogenic effect of oral contraceptive pills?. Contraception 74 (2006) 245-248